Dividend Dispatch — Today's Theme
Today's Theme
A 1% yield can hand you more cash in ten years than a 6% one. Here's the math nobody runs.
I'll be straight: the two Growth Stars today pay about 1%. I can hear the groan. But American Express just raised its dividend 16%, and Cintas has raised for 42 straight years — both paying out barely a third of what they earn. That low number is the whole point: it means the raises can keep coming. Then in Safety I've got Johnson & Johnson, one of two AAA-rated companies in America, and Pfizer — a 6.6% yield I want you to see clearly before you reach for it.

You Left $29.97 On The Table

Your free download link is about to expire.

Once it does — this guide goes back to $29.97.

Inside: options trading explained in plain English. No jargon. No textbook talk. Real trade examples you can copy directly into your own account.

Calls. Puts. Strikes. Premiums. All of it — explained the way a friend would explain it over coffee.

Grab your free copy before the link dies.

Dividend Dispatch — Section 1a
🚀
Dividend Growth Stars
Fast-rising income builders
AXPAmerican Express just raised its dividend 16% — and it barely felt it
You know American Express — the card, the lounges, the swipe fees it collects from merchants on every purchase. In March the board lifted the quarterly dividend 16%, to $0.95 from $0.82, taking the annual payout to $3.80. On a roughly $338 share that's about 1.1%, which I know looks tiny. So here's the number that matters more than the yield: the payout ratio — the share of profit that goes out as dividends. Amex pays out only about 21% of what it earns. That means $4 of every $5 in profit stays in the business, and the dividend has enormous room to keep climbing — it's grown around 16% a year lately. A 1.1% yield that rises 16% a year overtakes a frozen 6% yield faster than most people expect. The risk is real: Amex lives on consumer spending, so a recession hits its cardholders and its loan losses at the same time. But the dividend itself is buried under earnings. Ex-date is July 2.
Yield: 1.1% $10K invested = $112/yr Paid: Quarterly
Dividend Dispatch — Section 1b
CTASThe boring uniform company that's raised its dividend 42 years straight
Cintas rents work uniforms, floor mats, restroom supplies and first-aid kits to hundreds of thousands of businesses — the dull, recurring stuff a company pays for every month without thinking. That's the beauty of it: the revenue shows up on contract, year after year. Cintas pays $1.80 a year ($0.45 a quarter) on a roughly $176 share, about 1.0%. Again, small yield — but look at the engine. It just extended its streak to 42 consecutive years of increases, the latest raise was 15%, and it pays out only about 35% of earnings. Low payout plus steady raises is the exact profile I hunt for in this section: a dividend with decades of road ahead. The honest risk: the stock isn't cheap, trading around 50 times earnings, so you're paying up for that reliability — and one analyst note flagged that automation could slowly chip at demand for uniform services over many years. Neither threatens this year's check. Both are worth watching.
Yield: 1.0% $10K invested = $103/yr Paid: Quarterly
Dividend Dispatch — Main Rest
🛡️
Safety & Watchlist
Reliable picks + red flags
Safe Pick
JNJJohnson & Johnson — 64 years of raises and a credit rating the U.S. government can't match
Band-Aids, Tylenol, surgical tools, cancer drugs — Johnson & Johnson sells health products people buy whether the economy is booming or breaking. In April it raised the dividend 3.1%, to $1.34 a quarter, marking 64 straight years of increases. On a roughly $229 share that's about 2.3%. Here's what earns it the "safe" badge: J&J holds a AAA credit rating — it's one of only two American companies rated that highly, a stronger rating than the U.S. Treasury itself carries. And it pays out about 60% of earnings, a comfortable cushion that lets the raises continue without strain. The honest caveat: this isn't a fast grower — raises have run around 5% a year, and the company still carries talc-lawsuit liabilities that flare up in headlines. But for the steady, sleep-easy core of an income portfolio, few names are sturdier.
Yield: 2.3% $10K invested = $234/yr Paid: Quarterly
Red Flag
PFEPfizer's 6.6% looks great until you read the second payout ratio
Pfizer makes the headline-grabbing yield in big pharma right now — about 6.6%, $1.72 a year on a roughly $26 share, with a 350-quarter payment history stretching back to 1937. So why the red flag? Because there are two payout ratios, and they tell opposite stories. On the company's adjusted earnings, the dividend eats about 53%. But on standard GAAP earnings — the audited kind — the payout sits north of 125%, meaning Pfizer paid out more than it actually earned. In 2025 the dividend even ran ahead of free cash flow. The tell I can't ignore: the December raise was a single penny, and the rate's been frozen at $0.43 since. A board that guards a six-decade streak doesn't freeze the raise casually. Analysts expect earnings to keep sliding as old blockbusters lose patent protection. The 6.6% is the market pricing in a possible cut — not a gift. I'd want to see coverage recover before I trusted that check.
📋
The Extra Yield
This week's calendars, screens & answers
Don't miss this ex-date: American Express goes ex-dividend July 2 — own it before that morning to collect the $0.95 quarterly payment on August 10. Cintas already went ex on May 15, so its next one is the one to watch for in August.
I ran a screen this morning: low yield, low payout ratio, double-digit raises. Beyond today's AXP and CTAS, the same filter turned up Visa and Mastercard — both paying under 1% but with payout ratios near 20% and decades of room. Quiet compounders hiding behind small headline yields.
Someone asked me: "Pfizer pays 6.6% and Amex pays 1.1% — isn't Pfizer the better income stock?" Today, yes — $660 a year versus $112 on $10K. But Pfizer's payout is frozen and stretched past 100% of GAAP earnings, while Amex's grows 16% a year. Give it a decade and the gap closes fast. Yield is today's number; growth is tomorrow's.
The Dispatch
Today was about reading past the yield. American Express (16% raise) and Cintas (42 years running) prove a 1% payout can be the better income bet, Johnson & Johnson is the AAA anchor, and Pfizer's 6.6% is the trap to study. Tomorrow's the Weekly Roundup — my single best pick from every section, the whole week in one place. See you then.
— Charlie

Recommended publications

View more
caret-right